An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
dc.contributor.author | Vij, Ravi | en_US |
dc.contributor.author | Siegel, David S. | en_US |
dc.contributor.author | Jagannath, Sundar | en_US |
dc.contributor.author | Jakubowiak, Andrzej J. | en_US |
dc.contributor.author | Stewart, Alexander Keith | en_US |
dc.contributor.author | McDonagh, Kevin | en_US |
dc.contributor.author | Bahlis, Nizar | en_US |
dc.contributor.author | Belch, Andrew | en_US |
dc.contributor.author | Kunkel, Lori A. | en_US |
dc.contributor.author | Wear, Sandra | en_US |
dc.contributor.author | Wong, Alvin F. | en_US |
dc.contributor.author | Wang, Michael | en_US |
dc.date.accessioned | 2012-09-05T14:46:17Z | |
dc.date.available | 2013-10-18T17:47:30Z | en_US |
dc.date.issued | 2012-09 | en_US |
dc.identifier.citation | Vij, Ravi; Siegel, David S.; Jagannath, Sundar; Jakubowiak, Andrzej J.; Stewart, Alexander Keith; McDonagh, Kevin; Bahlis, Nizar; Belch, Andrew; Kunkel, Lori A.; Wear, Sandra; Wong, Alvin F.; Wang, Michael (2012). "An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib." British Journal of Haematology 158(6): 739-748. <http://hdl.handle.net/2027.42/93582> | en_US |
dc.identifier.issn | 0007-1048 | en_US |
dc.identifier.issn | 1365-2141 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/93582 | |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.publisher | American Cancer Society Inc | en_US |
dc.subject.other | Multiple Myeloma | en_US |
dc.subject.other | Proteasome Inhibitor | en_US |
dc.subject.other | Relapsed | en_US |
dc.subject.other | Refractory | en_US |
dc.subject.other | Phase 2 | en_US |
dc.title | An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.identifier.pmid | 22845873 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/93582/1/bjh9232.pdf | |
dc.identifier.doi | 10.1111/j.1365-2141.2012.09232.x | en_US |
dc.identifier.source | British Journal of Haematology | en_US |
dc.identifier.citedreference | O'Connor, O.A., Stewart, A.K., Vallone, M., Molineaux, C.J., Kunkel, L.A., Gerecitano, J.F. & Orlowski, R.Z. ( 2009 ) A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR‐171) in patients with hematologic malignancies. Clinical Cancer Research, 15, 7085 – 7091. | en_US |
dc.identifier.citedreference | Dispenzieri, A., Rajkumar, S.V., Gertz, M.A., Fonseca, R., Lacy, M.Q., Bergsagel, P.L., Kyle, R.A., Greipp, P.R., Witzig, T.E., Reeder, C.B., Lust, J.A., Russell, S.J., Hayman, S.R., Roy, V., Kumar, S., Zeldenrust, S.R., Dalton, R.J. & Stewart, A.K. ( 2007 ) Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk‐adapted Therapy (mSMART): consensus statement. Mayo Clinic Proceedings, 82, 323 – 341. | en_US |
dc.identifier.citedreference | van de Donk, N.W., Lokhorst, H.M., Dimopoulos, M., Cavo, M., Morgan, G., Einsele, H., Kropff, M., Schey, S., Avet‐Loiseau, H., Ludwig, H., Goldschmidt, H., Sonneveld, P., Johnsen, H.E., Blade, J., San‐Miguel, J.F. & Palumbo, A. ( 2011 ) Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Reviews, 37, 266 – 283. | en_US |
dc.identifier.citedreference | Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. ( 2006 ) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467 – 1473. | en_US |
dc.identifier.citedreference | Greipp, P.R., San Miguel, J., Durie, B.G., Crowley, J.J., Barlogie, B., Blade, J., Boccadoro, M., Child, J.A., Avet‐Loiseau, H., Kyle, R.A., Lahuerta, J.J., Ludwig, H., Morgan, G., Powles, R., Shimizu, K., Shustik, C., Sonneveld, P., Tosi, P., Turesson, I. & Westin, J. ( 2005 ) International staging system for multiple myeloma. Journal of Clinical Oncology, 23, 3412 – 3420. | en_US |
dc.identifier.citedreference | Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. & Anderson, K.C. ( 2001 ) The proteasome inhibitor PS‐341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 3071 – 3076. | en_US |
dc.identifier.citedreference | Huang, H.Q., Brady, M.F., Cella, D. & Fleming, G. ( 2007 ) Validation and reduction of FACT/GOG‐Ntx subscale for platinum/paclitaxel‐induced neurologic symptoms: a gynecologic oncology group study. International Journal of Gynecological Cancer, 17, 387 – 393. | en_US |
dc.identifier.citedreference | Kanayama, H., Tanaka, K., Aki, M., Kagawa, S., Miyaji, H., Satoh, M., Okada, F., Sato, S., Shimbara, N. & Ichihara, A. ( 1991 ) Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Research, 51, 6677 – 6685. | en_US |
dc.identifier.citedreference | Kane, R.C., Bross, P.F., Farrell, A.T. & Pazdur, R. ( 2003 ) Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. The Oncologist, 8, 508 – 513. | en_US |
dc.identifier.citedreference | Kirk, C.J., Jiang, J., Muchamuel, T., Dajee, M., Swinarski, D., Aujay, M., Bennett, M.K., Yang, J., Lewis, E., Laidig, G. & Molineaux, C.J. ( 2008 ) The Selective Proteasome Inhibitor Carfilzomib Is Well Tolerated in Experimental Animals with Dose Intensive Administration. Blood (ASH Annual Meeting Abstracts), 112, A2765. | en_US |
dc.identifier.citedreference | Kuhn, D.J., Chen, Q., Voorhees, P.M., Strader, J.S., Shenk, K.D., Sun, C.M., Demo, S.D., Bennett, M.K., van Leeuwen, F.W., Chanan‐Khan, A.A. & Orlowski, R.Z. ( 2007 ) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin‐proteasome pathway, against preclinical models of multiple myeloma. Blood, 110, 3281 – 3290. | en_US |
dc.identifier.citedreference | Kyle, R.A. & Rajkumar, S.V. ( 2008 ) Multiple myeloma. Blood, 111, 2962 – 2972. | en_US |
dc.identifier.citedreference | Laubach, J.P., Richardson, P.G. & Anderson, K.C. ( 2010 ) The evolution and impact of therapy in multiple myeloma. Medical Oncology, 27 ( Suppl 1 ), S1 – S6. | en_US |
dc.identifier.citedreference | Martin, T., Singhal, S.B., Vij, R.M.W., Stewart, A.K., Jagganath, S., Lonial, S., Jakubowiak, A.J., Kukreti, V., Bahlis, N.J., Alsina, M., Chanan‐Khan, A.A., Somlo, G., Buadi, F., Reu, F.J., Zonder, J.A., Song, K., Stadtmauer, E.A., Wong, A.F., Vallone, M., Chang, Y.‐L., Kauffman, M., Orlowski, R.Z. & Siegel, D.S.D. ( 2010 ) Baseline peripheral neuropathy does not impact the efficacy and tolerability of the novel proteasome inhibitor carfilzomib (CFZ): results of a subset analysis of a phase 2 trial In patients with relapsed and refractory multiple myeloma (R/R MM). Blood (ASH Annual Meeting Abstracts), 116, A3031. | en_US |
dc.identifier.citedreference | Mohty, B., El‐Cheikh, J., Yakoub‐Agha, I., Moreau, P., Harousseau, J.L. & Mohty, M. ( 2010 ) Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica, 95, 311 – 319. | en_US |
dc.identifier.citedreference | Mohty, B., El‐Cheikh, J., Yakoub‐Agha, I., Avet‐Loiseau, H., Moreau, P. & Mohty, M. ( 2012 ) Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents. Leukemia, 26, 73 – 85. | en_US |
dc.identifier.citedreference | Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., Arnulf, B., Kropff, M., Cavet, J., Esseltine, D.L., Feng, H., Girgis, S., van de Velde, H., Deraedt, W. & Harousseau, J.L. ( 2011 ) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non‐inferiority study. The Lancet Oncology, 12, 431 – 440. | en_US |
dc.identifier.citedreference | Niesvizky, R., Richardson, P.G., Rajkumar, S.V., Coleman, M., Rosinol, L., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Boral, A.L., Esseltine, D.L., Anderson, K.C. & Blade, J. ( 2008 ) The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. British Journal of Haematology, 143, 46 – 53. | en_US |
dc.identifier.citedreference | Papadopoulos, K., Lee, P., Singhal, S., Holahan, J., Tolcher, A., Patnaik, A., Vesole, D., Rosen, S., Rosen, P., Bilotti, E., Woo, T., Lee, S., Hannah, A. & Siegel, D. ( 2011 ) PX‐171‐007: a phase 1b study evaluating the safety and efficacy of a 30‐minute IV infusion of carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma (MM) (Abstract 0898). Haematologica (Abstracts from the 16th Annual Congress of the EHA), 96, 374. | en_US |
dc.identifier.citedreference | Parlati, F., Lee, S.J., Aujay, M., Suzuki, E., Levitsky, K., Lorens, J.B., Micklem, D.R., Ruurs, P., Sylvain, C., Lu, Y., Shenk, K.D. & Bennett, M.K. ( 2009 ) Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin‐like activity of the proteasome. Blood, 114, 3439 – 3447. | en_US |
dc.identifier.citedreference | Plosker, G.L. ( 2008 ) Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs, 68, 2535 – 2551. | en_US |
dc.identifier.citedreference | Rajkumar, S.V. ( 2009 ) Multiple myeloma. Current Problems in Cancer, 33, 7 – 64. | en_US |
dc.identifier.citedreference | Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San‐Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. ( 2005 ) Bortezomib or high‐dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487 – 2498. | en_US |
dc.identifier.citedreference | Siegel, D., Martin, T., Wang, M., Vij, R., Jakubowiak, A.J., Jagannath, S., Lonial, S., Kukreti, V., Bahlis, N.J., Alsina, M., Chanan‐Khan, A.A., Somlo, G., Buadi, F., Reu, F.J., Zonder, J.A., Song, K., Stadtmauer, E., Wong, A.F., Vallone, M., Chang, Y.‐L., Kauffman, M., Orlowski, R.Z., Stewart, A.K. & Singhal, S.B. ( 2010 ) The multiple myeloma research consortium results of PX‐171‐003‐A1, an open‐label, single‐arm, phase 2 (ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts), 116, A985. | en_US |
dc.identifier.citedreference | Siegel, R., Ward, E., Brawley, O. & Jemal, A. ( 2011a ) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: A Cancer Journal for Clinicians, 61, 212 – 236. | en_US |
dc.identifier.citedreference | Siegel, S., Kaufman, J., Wang, M., Martin, T., Jagannath, S., Niesvizky, R., Reu, F., Alsina, M., Badros, A., Gabrail, N., Kukreti, V., Singhal, S., Le, M., Kotlovker, D., Bomba, D., Hannah, A. & Vij, R. ( 2011b ) A summary of safety and efficacy data achieved with long‐term carfilzomib (CFZ) treatment in patients with relapsed and/or refractory multiple myeloma (R/R MM) Haematologica, 96, 126, Abstract 0302. | en_US |
dc.identifier.citedreference | Siegel, D., Martin, T., Wang, M., Vij, R., Lonial, S., Kukreti, V., Bahlis, N., Alsina, M., Somlo, G., Buadi, F., Reu, F., Song, K., Kunkel, L.A., Wong, A.F., Vallone, M., Orlowski, R., Stewart, A.K., Singhal, S., Jagannath, S. & Jakubowiak, A. ( 2011c ) PX‐171‐003‐A1, an open‐label, single‐arm phase (Ph) 2 study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): long‐term follow‐up and subgroup analysis. Journal of Clinical Oncology (Meeting Abstracts), 29, Abstract 8027. | en_US |
dc.identifier.citedreference | Singhal, S., Siegel, D.S., Martin, T., Vij, R., Wang, L., Jakubowiak, A.J., Lonial, S., Kukreti, V., Zonder, J.A., Wong, A.F., McCulloch, L., Badros, A.Z., Niesvizky, R., Orlowski, R.Z., Stewart, A.K., Kotlovker, D. & Jagannath, S. ( 2011 ) Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis. Blood (ASH Annual Meeting Abstracts), 118, Abstract 1876. | en_US |
dc.identifier.citedreference | Vij, R., Kaufman, J.L., Jakubowiak, A.J., Stewart, A.K., Jagannath, S., Kukreti, V., McDonagh, K.T., Alsina, M., Bahlis, N.J., Belch, A., Reu, F.J., Gabrail, N.Y., Matous, J., Vesole, D.H., Orlowski, R.Z., Le, M.H., Lee, P., Wang, M. & the Multiple Myeloma Research Consortium. ( 2010 ) Carfilzomib: high single agent response rate with minimal neuropathy even in high‐risk patients (Abstract). Blood (ASH Annual Meeting Abstracts), 116; Abstract 1938. | en_US |
dc.identifier.citedreference | Vij, R., Wang, M., Kaufman, J., Lonial, S., Jakubowiak, A., Stewart, A., Kukreti, V., Jagannath, S., McDonagh, K., Alsina, M., Bahlis, N., Reu, F., Gabrail, N., Belch, A., Matous, J., Lee, P., Rosen, P., Sebag, M., Vesole, D., Kunkel, L., Wear, S., Wong, A., Orlowski, R. & Siegel, D.S. ( 2012 ) An open‐label, single‐arm, phase 2 (PX‐171‐004) study of single‐agent carfilzomib in bortezomib‐naïve patients with relapsed and/or refractory multiple myeloma. Blood, 119, 5661 – 5670. | en_US |
dc.identifier.citedreference | ACS. ( 2012 ). Cancer Facts & Figures 2012. American Cancer Society Inc., Atlanta, GA, USA. | en_US |
dc.identifier.citedreference | Alsina, M., Trudel, S., Vallone, M., Molineaux, C., Kunkel, L. & Goy, A. ( 2007 ) Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR‐171) in hematologic malignancies. Blood (ASH Annual Meeting Abstracts), 110, A411. | en_US |
dc.identifier.citedreference | Arastu‐Kapur, S., Anderl, J.L., Kraus, M., Parlati, F., Shenk, K.D., Lee, S.J., Muchamuel, T., Bennett, M.K., Driessen, C., Ball, A.J. & Kirk, C.J. ( 2011 ) Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clinical Cancer Research, 17, 2734 – 2743. | en_US |
dc.identifier.citedreference | Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. ( 1998 ) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high‐dose therapy and haemopoietic stem cell transplantation. British Journal of Haematology, 102, 1115 – 1123. | en_US |
dc.identifier.citedreference | Boyette‐Davis, J.A., Cata, J.P., Zhang, H., Driver, L.C., Wendelschafer‐Crabb, G., Kennedy, W.R. & Dougherty, P.M. ( 2011 ) Follow‐up psychophysical studies in bortezomib‐related chemoneuropathy patients. Journal of Pain, 12, 1017 – 1024. | en_US |
dc.identifier.citedreference | Bringhen, S., Larocca, A., Rossi, D., Cavalli, M., Genuardi, M., Ria, R., Gentili, S., Patriarca, F., Nozzoli, C., Levi, A., Guglielmelli, T., Benevolo, G., Callea, V., Rizzo, V., Cangialosi, C., Musto, P., De Rosa, L., Liberati, A.M., Grasso, M., Falcone, A.P., Evangelista, A., Cavo, M., Gaidano, G., Boccadoro, M. & Palumbo, A. ( 2010 ) Efficacy and safety of once‐weekly bortezomib in multiple myeloma patients. Blood, 116, 4745 – 4753. | en_US |
dc.identifier.citedreference | Demo, S.D., Kirk, C.J., Aujay, M.A., Buchholz, T.J., Dajee, M., Ho, M.N., Jiang, J., Laidig, G.J., Lewis, E.R., Parlati, F., Shenk, K.D., Smyth, M.S., Sun, C.M., Vallone, M.K., Woo, T.M., Molineaux, C.J. & Bennett, M.K. ( 2007 ) Antitumor activity of PR‐171, a novel irreversible inhibitor of the proteasome. Cancer Research, 67, 6383 – 6391. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.